III. Introduction
During the past fifteen years, treatment of hematologic malignancies changed radically.
In 1997, the FDA approved rituximab, now widely used to treat hematologic malignancies including NHL. Later, tyrosine kinase inhibitors (TKIs) were introduced to treat CML. TKIs exceeded survival benefit expectations 1 ; however, they also have a notably high cost.
The first TKI, imatinib, was introduced in 2001 at roughly $30,000/year of treatment.
Others, introduced more recently, cost roughly $100,000/year or more. 2 These prices have prompted significant outcry, with some questioning whether these medications provide good value for money. 2 The use of bortezomib, a proteasome inhibitor, and novel anti-angiogenesis agent lenalidomide have improved MM outcomes. These and other innovative treatments have increased patients' life expectancy.
1, 3
Cost-effectiveness analysis (CEA) is a technique to assess interventions' benefit relative to costs. Cost-utility analysis (CUA) is a type of CEA that measures health benefits in qualityadjusted life-years (QALYs). This generic measure facilitates comparison of health care interventions addressing varied conditions. CUA has been used extensively in oncology. 4 We identified innovative treatments for hematologic malignancies and performed a systematic review of peer-reviewed CUAs. It is important to understand the current literature regarding these treatments, which have undergone dramatic changes in cost and effectiveness.
We synthesized analyses of care for hematologic malignancies, examined the number, quality, and related characteristics of analyses, and summarized cost-utility ratios by treatment and disease types. To our knowledge, this review is the first of its kind.
IV.

Methods
We analyzed data from the Tufts CEA Registry (www.cearegistry.org), a database of over 9800 cost-effectiveness ratios published in the peer-reviewed medical and economic literature through 2012. The Registry's development and inclusion criteria are described elsewhere. 5 Briefly, English-language publications identified by a MEDLINE search that contain an original cost per QALY estimate are retrieved. Two trained researchers evaluate articles for inclusion and extract article information. Disagreement is resolved by consensus.
Our review included studies that addressed treatment for hematologic malignancies. We excluded review, editorial, or methodological articles, CEAs that did not measure health effects in QALYs, and non-English-language articles. We included therapeutic agents the FDA approved since 1997 and excluded hematopoietic stem cell transplant, symptom management, and supportive care. The studies were manually checked for duplication. No duplicates were found.
We collected data regarding study origin, methods, and reporting of results. For each CUA, descriptive characteristics collected included publication year, country of origin, intervention type, publication journal, funding source, and methodological and analytic characteristics including study perspective, discounting of future costs and life-years, whether economic data were collected alongside a clinical trial, and type of sensitivity analysis performed (i.e., univariate, multivariable, or probabilistic). Each study was assigned a subjective quality score on a Likert scale from 1 (low) to 7 (high) based on rigor of methodology, presentation, and value to decision-makers. We conducted a sub-group analysis of ICER distributions including only high quality scores with a quality score of 5 or higher and compared this analysis with the distribution in all studies.
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We grouped studies into four subcategories by cancer type: CLL, CML, MM, and NHL, and nine treatment agents: α interferon, alemtuzumab, bendamustine, bortezomib, dasatinib, imatinib, lenolidomide, rituximab alone or in combination, and thalidomide. Some studies contributed multiple ICERs, because they compared several interventions or included scenarios for multiple settings. For analysis, we assigned each ratio a statistical weight of 1 divided by the number of ratios contributed by that study. ). The pharmaceutical industry funded 22 studies (76%). Six studies collected economic data alongside a clinical trial. The mean quality rating was 4.85 (±0.61) (the mean rating overall in the Registry was 4.45 (±1.03)). The mean quality rating was analyzed using a two-tailed t-test and did not differ significantly between industry and non-industry-funded studies.
V. Results and discussion
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The studies reported 44 cost-effectiveness ratios (some studies report multiple ratios).
Most ratios addressed interventions for NHL (41%) or CML (30%). Most ratios pertained to treatments for rituximab (43%), α interferon (18%), or imatinib (16%). The most common intervention-disease combination was rituximab alone or in combination for NHL (36%).
Across cancers, the median reported ratio was highest for CML ($55,000/QALY) and The median ratio reported by industry-funded studies ($26,000/QALY) was lower (more favorable) than the median reported by non-industry-funded studies ($33,000/QALY). These differences were analyzed using a chi-square test and results for trends across time periods were confirmed with a logistics regression; the differences were not statistically significant.
Most ratios fell below (were more favorable than) the $50,000/QALY (73%) or $100,000/QALY (86%) threshold (Figure 1 ). These thresholds are commonly used in the US as benchmarks for cost-effectiveness. Although their origins are unclear, evidence suggests that thresholds at these levels or higher may be appropriate depending on the context. 8 (A higher threshold would expand the range of analyses that are considered cost-effective, which would mean that our analysis is conservative and more of the CEAs included should be considered costeffective). Four ratios, one industry-funded, exceeded $100,000/QALY, including two pertaining to treatment of MM with bortezomib, 9, 10 one pertaining to treatment of CML with α interferon, 11 and one pertaining to treatment of CML with imatinib. In two cases, both industry-funded, (alemtuzumab to treat CLL and bortezomib to treat MM), the treatment improved health and reduced costs.
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The distribution of ICERs by value in the high quality (quality score >= 5) subsample was similar to the distribution in all studies, yielding findings that were not significantly different than those in the overall analysis. For example, when comparing ICERs from industry-and nonindustry-funded-studies in the high quality subsample, there was not a statistically significant different in the number of ICERs with values greater than over equal to $100,000/QALY.
Our review suggests many new treatments for hematologic malignancies may confer reasonable value for money. Despite the high costs of new drugs, the cost-effectiveness ratio distributions are comparable to those for cancers overall and other health care fields. 4, 12 For example, a 2010 study found the majority of published cost-effectiveness ratios for cancer interventions were below $50,000/QALY. 4 As in similar reviews, our results may reflect publication bias. 12 In particular, they may reflect selective conduct of studies and underreporting of unfavorable findings, particularly by industry-funded studies, which were a majority of reviewed studies.
12
Treatments for NHL may appear more cost-effective than treatment for CML, because innovative agents such as rituximab for NHL were introduced in earlier years than TKIs for CML, which may have affected the manufacturers' pricing strategies. In addition, unlike rituximab, the TKI market has experienced a flurry of agents approved for the same target.
Churning in this market based on loss of efficacy, concern about gene mutation, differences in dosing administration (e.g. daily vs twice daily), and side effect profiles may results in increasing costs for CML treatment as compared with NHL.
We believe that this kind of global overview of the literature will be useful to provide a broad perspective for clinicians on how their individual focus relates to associated interventions and malignancies. In the context of recent discussions about the cost-effectiveness of various interventions in the popular media, it may be particularly useful for clinicians to understand the literature in the field as a whole. We appreciate that individual clinicians may concentrate on specific malignancies and therapies, and we have therefore included data that we hope will be useful in these circumstances regarding the proportion of studies and median ratios for specific diseases and interventions.
Faced with rising costs, many payers use economic analyses to inform coverage decisions; frequently, they limit access to expensive new drugs. 13 For example, after reviewing the cost-effectiveness evidence, the UK's National Institute for Health and Clinical Excellence recently approved nilotinib, a second generation TKI, but only after the manufacturer discounted it.
14 Our study has several limitations. First, our review only includes CEAs in the Tufts CEA In summary, many new treatments for hematologic malignancies appear to be costeffective based on the published literature. Industry-funded studies reported a lower (more favorable) median ratio than non-industry funded studies. However, both groups reported medians below $50,000/QALY. Although prices are high, the treatments confer substantial health benefits as measured by QALYs. However, decision-makers consider factors other than cost-effectiveness (e.g., health impact, values, preferences, overall budget impact, affordability for patients) and determine how best to weight these factors according to the situation at hand. 16, 17 Decision-makers can use cost-effectiveness as one tool when determining appropriate coverage for these and other drugs.
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